Glenmark Pharmaceuticals Share Price
Sector: Biotechnology & Drugs
You have to be logged in to add this to Watchlist.
Login or Register
1464.90 -27.45 (-1.84%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
1458.85
Today’s High
1494.45
52 Week Low
761.15
52 Week High
1830.05
1466.40 -26.25 (-1.76%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
1458.55
Today’s High
1494.2
52 Week Low
761
52 Week High
1830.95
Glenmark Pharmaceuticals Analysis
Risk Meter
- 31% Low risk
- 31% Moderate risk
- 31% Balanced Risk
- 31% High risk
- 31% Extreme risk
Recos
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- 1 W Ago
- 1 M Ago
- 3 M Ago
- Strong Buy
- 4
- 4
- 4
- 4
- Buy
- 1
- 1
- 1
- 2
- Hold
- 4
- 4
- 4
- 3
- Sell
- 1
- 1
- 1
- 1
- Strong Sell
- 0
- 0
- 0
- 0
- Total
- 10
- 10
- 10
- 10
Glenmark Pharmaceuticals News
Stocks to Watch: Zomato, Nykaa, Hero MotoCorp, RIL, Godrej Properties, and more
1 min read . 18 Nov 2024Glenmark Pharma Q2 Results: Pharma major posts net profit of ₹354.48 crore
1 min read . 14 Nov 2024Stocks to Watch: Adani Green, KEC Intl, Venus Pipes, Glenmark Pharma, and more
3 min read . 06 Sep 2024Glenmark Pharmaceuticals Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2024
- Total Revenue
- 11813.1
- Selling/ General/ Admin Expenses Total
- 2868.14
- Depreciation/ Amortization
- 581.91
- Other Operating Expenses Total
- 3336.25
- Total Operating Expense
- 12100.63
- Operating Income
- -287.53
- Net Income Before Taxes
- 36.5
- Net Income
- -1501.67
- Diluted Normalized EPS
- -46.55
- Period
- 2024
- Total Assets
- 14358.62
- Total Liabilities
- 6510.7
- Total Equity
- 7847.93
- Tangible Book Valueper Share Common Eq
- 230.81
- Period
- 2024
- Cashfrom Operating Activities
- -457.2
- Cashfrom Investing Activities
- 4560.89
- Cashfrom Financing Activities
- -3906.13
- Net Changein Cash
- 215.24
- Period
- 2023
- Total Revenue
- 11583.24
- Selling/ General/ Admin Expenses Total
- 2600.78
- Depreciation/ Amortization
- 569.17
- Other Operating Expenses Total
- 3089.92
- Total Operating Expense
- 11283.26
- Operating Income
- 299.98
- Net Income Before Taxes
- 239.84
- Net Income
- 297.24
- Diluted Normalized EPS
- 11.62
- Period
- 2023
- Total Assets
- 19371.68
- Total Liabilities
- 9897.75
- Total Equity
- 9473.92
- Tangible Book Valueper Share Common Eq
- 250.12
- Period
- 2023
- Cashfrom Operating Activities
- 626.06
- Cashfrom Investing Activities
- -528.49
- Cashfrom Financing Activities
- -77.46
- Net Changein Cash
- 32.5
- Period
- 2022
- Total Revenue
- 12304.9
- Selling/ General/ Admin Expenses Total
- 3374.22
- Depreciation/ Amortization
- 486.72
- Other Operating Expenses Total
- 1625.11
- Total Operating Expense
- 10725.77
- Operating Income
- 1579.14
- Net Income Before Taxes
- 1441.25
- Net Income
- 941.71
- Diluted Normalized EPS
- 39.91
- Period
- 2022
- Total Assets
- 17083.29
- Total Liabilities
- 7996.64
- Total Equity
- 9086.65
- Tangible Book Valueper Share Common Eq
- 241.04
- Period
- 2022
- Cashfrom Operating Activities
- 1108.65
- Cashfrom Investing Activities
- -333.28
- Cashfrom Financing Activities
- -520.49
- Net Changein Cash
- 272.43
- Period
- 2021
- Total Revenue
- 10943.93
- Selling/ General/ Admin Expenses Total
- 3242.35
- Depreciation/ Amortization
- 443.55
- Other Operating Expenses Total
- 1290.01
- Total Operating Expense
- 9258.56
- Operating Income
- 1685.37
- Net Income Before Taxes
- 1382.48
- Net Income
- 970.09
- Diluted Normalized EPS
- 33.26
- Period
- 2021
- Total Assets
- 15603.58
- Total Liabilities
- 8538.95
- Total Equity
- 7064.63
- Tangible Book Valueper Share Common Eq
- 167.62
- Period
- 2021
- Cashfrom Operating Activities
- 1131.21
- Cashfrom Investing Activities
- -675.24
- Cashfrom Financing Activities
- -441.78
- Net Changein Cash
- 27.82
- Period
- 2020
- Total Revenue
- 10640.97
- Selling/ General/ Admin Expenses Total
- 3254.42
- Depreciation/ Amortization
- 417.17
- Other Operating Expenses Total
- 1478.54
- Total Operating Expense
- 9326
- Operating Income
- 1314.96
- Net Income Before Taxes
- 1096.08
- Net Income
- 775.97
- Diluted Normalized EPS
- 26.7
- Period
- 2020
- Total Assets
- 14684.81
- Total Liabilities
- 8614.3
- Total Equity
- 6070.5
- Tangible Book Valueper Share Common Eq
- 137.8
- Period
- 2020
- Cashfrom Operating Activities
- 1392.41
- Cashfrom Investing Activities
- -783.52
- Cashfrom Financing Activities
- -444.66
- Net Changein Cash
- 174
- Period
- 2019
- Total Revenue
- 9865.47
- Selling/ General/ Admin Expenses Total
- 3188.08
- Depreciation/ Amortization
- 325.91
- Other Operating Expenses Total
- 1162.3
- Total Operating Expense
- 8438.39
- Operating Income
- 1427.08
- Net Income Before Taxes
- 1300.63
- Net Income
- 924.99
- Diluted Normalized EPS
- 28.55
- Period
- 2019
- Total Assets
- 13295.65
- Total Liabilities
- 7690.46
- Total Equity
- 5605.18
- Tangible Book Valueper Share Common Eq
- 137.09
- Period
- 2019
- Cashfrom Operating Activities
- 1324.17
- Cashfrom Investing Activities
- -698.99
- Cashfrom Financing Activities
- -738.74
- Net Changein Cash
- -297.08
- Period
- 2018
- Total Revenue
- 9103.07
- Selling/ General/ Admin Expenses Total
- 3624.5
- Depreciation/ Amortization
- 354.07
- Other Operating Expenses Total
- 309.1
- Total Operating Expense
- 7842.11
- Operating Income
- 1260.96
- Net Income Before Taxes
- 1066.8
- Net Income
- 774.19
- Diluted Normalized EPS
- 27.5
- Period
- 2018
- Total Assets
- 13020.96
- Total Liabilities
- 7431.9
- Total Equity
- 5589.05
- Tangible Book Valueper Share Common Eq
- 144.55
- Period
- 2018
- Cashfrom Operating Activities
- 1648.05
- Cashfrom Investing Activities
- -1013.34
- Cashfrom Financing Activities
- -468.5
- Net Changein Cash
- 176.99
- Period
- 2024-09-30
- Total Revenue
- 3433.8
- Selling/ General/ Admin Expenses Total
- 786.56
- Depreciation/ Amortization
- 120.28
- Other Operating Expenses Total
- 975.24
- Total Operating Expense
- 2952.16
- Operating Income
- 481.63
- Net Income Before Taxes
- 472.57
- Net Income
- 354.21
- Diluted Normalized EPS
- 12.55
- Period
- 2024-09-30
- Total Assets
- 15235.34
- Total Liabilities
- 6789.68
- Total Equity
- 8445.66
- Tangible Book Valueper Share Common Eq
- 251.39
- Period
- 2024-09-30
- Cashfrom Operating Activities
- -783.02
- Cashfrom Investing Activities
- 516.31
- Cashfrom Financing Activities
- 440.85
- Net Changein Cash
- 160.63
- Period
- 2024-06-30
- Total Revenue
- 3244.19
- Selling/ General/ Admin Expenses Total
- 710.44
- Depreciation/ Amortization
- 117.79
- Other Operating Expenses Total
- 835.45
- Total Operating Expense
- 2773.76
- Operating Income
- 470.42
- Net Income Before Taxes
- 462.33
- Net Income
- 340.27
- Diluted Normalized EPS
- 12.06
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 3062.95
- Selling/ General/ Admin Expenses Total
- 700.96
- Depreciation/ Amortization
- 151.34
- Other Operating Expenses Total
- 862.13
- Total Operating Expense
- 3156.73
- Operating Income
- -93.78
- Net Income Before Taxes
- 530.83
- Net Income
- -1218.28
- Diluted Normalized EPS
- -33.74
- Period
- 2024-03-31
- Total Assets
- 14358.62
- Total Liabilities
- 6510.7
- Total Equity
- 7847.93
- Tangible Book Valueper Share Common Eq
- 230.81
- Period
- 2024-03-31
- Cashfrom Operating Activities
- -457.2
- Cashfrom Investing Activities
- 4560.89
- Cashfrom Financing Activities
- -3906.13
- Net Changein Cash
- 215.24
- Period
- 2023-12-31
- Total Revenue
- 2506.7
- Selling/ General/ Admin Expenses Total
- 753.04
- Depreciation/ Amortization
- 147.08
- Other Operating Expenses Total
- 930.06
- Total Operating Expense
- 2939.15
- Operating Income
- -432.45
- Net Income Before Taxes
- -521.38
- Net Income
- -351.37
- Diluted Normalized EPS
- -14.89
- Period
- 2023-12-31
- Period
- 2023-12-31
- Period
- 2023-09-30
- Total Revenue
- 3207.38
- Selling/ General/ Admin Expenses Total
- 732.88
- Depreciation/ Amortization
- 141.45
- Other Operating Expenses Total
- 814.43
- Total Operating Expense
- 3211.97
- Operating Income
- -4.59
- Net Income Before Taxes
- -124.35
- Net Income
- -81.95
- Diluted Normalized EPS
- 0.38
- Period
- 2023-09-30
- Total Assets
- 20006.42
- Total Liabilities
- 10679.32
- Total Equity
- 9327.09
- Tangible Book Valueper Share Common Eq
- 244.55
- Period
- 2023-09-30
- Cashfrom Operating Activities
- 295.65
- Cashfrom Investing Activities
- -398.94
- Cashfrom Financing Activities
- 233.89
- Net Changein Cash
- 122.91
- Period
- 2023-06-30
- Total Revenue
- 3036.07
- Selling/ General/ Admin Expenses Total
- 681.27
- Depreciation/ Amortization
- 142.04
- Other Operating Expenses Total
- 729.64
- Total Operating Expense
- 2792.78
- Operating Income
- 243.29
- Net Income Before Taxes
- 151.4
- Net Income
- 149.93
- Diluted Normalized EPS
- 1.71
- Period
- 2023-06-30
- Period
- 2023-06-30
- Period
- 2023-03-31
- Total Revenue
- 11583.24
- Selling/ General/ Admin Expenses Total
- 2600.78
- Depreciation/ Amortization
- 569.17
- Other Operating Expenses Total
- 3089.92
- Total Operating Expense
- 11283.26
- Operating Income
- 299.98
- Net Income Before Taxes
- 239.84
- Net Income
- 297.24
- Diluted Normalized EPS
- 11.62
- Period
- 2023-03-31
- Total Assets
- 19371.68
- Total Liabilities
- 9897.75
- Total Equity
- 9473.92
- Tangible Book Valueper Share Common Eq
- 250.12
- Period
- 2023-03-31
- Cashfrom Operating Activities
- 626.06
- Cashfrom Investing Activities
- -528.49
- Cashfrom Financing Activities
- -77.46
- Net Changein Cash
- 32.5
- Period
- 2022-12-31
- Total Revenue
- 3100.18
- Selling/ General/ Admin Expenses Total
- 707.46
- Depreciation/ Amortization
- 151.51
- Other Operating Expenses Total
- 852.24
- Total Operating Expense
- 2743.78
- Operating Income
- 356.4
- Net Income Before Taxes
- 329.86
- Net Income
- 272.58
- Diluted Normalized EPS
- 5.26
- Period
- 2022-12-31
- Period
- 2022-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Glenmark Pharmaceuticals Technical
Moving Average
SMA
- 5 Day1524.66
- 10 Day1607.5
- 20 Day1646.19
- 50 Day1689.38
- 100 Day1583.1
- 300 Day1294.34
Glenmark Pharmaceuticals Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Alkem Laboratories
- 5601
- 75.75
- 1.37
- 6440
- 4382.25
- 66959.96
- Abbott India
- 27165
- -28.8
- -0.11
- 30499.9
- 21983.4
- 57723.72
- Glenmark Pharmaceuticals
- 1464.9
- -27.45
- -1.84
- 1830.05
- 761.15
- 41338.01
- Glaxosmithkline Pharmaceuticals
- 2376.5
- -59.75
- -2.45
- 3073.87
- 1557.92
- 40259.34
- IPCA Laboratories
- 1571.75
- -1.35
- -0.09
- 1708.7
- 1042
- 39875.3
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Alkem Laboratories
- 36.76
- 6.41
- 18.26
- 13.94
- Abbott India
- 48.16
- 15.64
- 30.46
- 17.26
- Glenmark Pharmaceuticals
- -
- 5.37
- 1.61
- 1.43
- Glaxosmithkline Pharmaceuticals
- 59.59
- 23.23
- 20.45
- 12.25
- IPCA Laboratories
- 60.9
- 6.31
- 14.98
- 12.25
Glenmark Pharmaceuticals Shareholding
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 14-Nov-24
- Quarterly Results
- 14-Aug-24
- Quarterly Results
- 24-May-24
- Audited Results & Final Dividend
- 14-Feb-24
- Quarterly Results
- 10-Nov-23
- Quarterly Results
- 11-Aug-23
- Quarterly Results
- 19-May-23
- Audited Results & Final Dividend
- 10-Feb-23
- Quarterly Results
- 11-Nov-22
- Quarterly Results
- 10-Aug-22
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 27-Sept-24
- 30-Aug-24
- AGM
- 09-Nov-23
- 06-Oct-23
- POM
- 29-Sept-23
- 25-Aug-23
- AGM
- 06-Aug-23
- 05-Jul-23
- POM
- 16-Apr-23
- 15-Mar-23
- POM
- 16-May-22
- 13-Apr-22
- POM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 24-May-24
- -
- 13-Sept-24
- 2.5
- 19-May-23
- -
- 18-Sept-23
- 2.5
- 30-May-22
- -
- 12-Sept-22
- 2.5
- 28-May-21
- -
- 08-Sept-21
- 2.5